News headlines about Hologic (NASDAQ:HOLX) have been trending somewhat positive on Thursday, Accern Sentiment reports. The research group rates the sentiment of media coverage by analyzing more than twenty million news and blog sources in real time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Hologic earned a media sentiment score of 0.12 on Accern’s scale. Accern also gave news articles about the medical equipment provider an impact score of 46.8401355604881 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the near term.
Here are some of the media stories that may have impacted Accern’s rankings:
- Worth Watching Stock for Traders: Hologic, Inc. (HOLX) (nysewired.com)
- Have a Path to Grow Up for Centene Corporation (CNC) and Hologic, Inc. (HOLX)? (nmsunews.com)
- Investors Attention Alert: Hologic, Inc. (HOLX) (nasdaqplace.com)
- Global Radiographic Film Processors Market 2018 Growth Analysis| Hitachi Medical Corporation, Hologic Inc, GE … (marketingsolution24.com)
- Global Mammography Equipment Market 2018 – Hologic，Inc, GE Healthcare, Siemens Healthcare (journalcommunication.com)
HOLX has been the topic of several research reports. Needham & Company LLC reaffirmed a “buy” rating and issued a $43.00 target price (down from $50.00) on shares of Hologic in a research report on Tuesday, May 1st. Goldman Sachs Group set a $43.00 target price on Hologic and gave the stock a “buy” rating in a research report on Tuesday, April 17th. BTIG Research reissued a “buy” rating and set a $44.00 price objective on shares of Hologic in a report on Sunday, May 6th. TheStreet lowered Hologic from a “b-” rating to a “c-” rating in a report on Wednesday, May 2nd. Finally, Zacks Investment Research lowered Hologic from a “buy” rating to a “hold” rating in a report on Tuesday, March 6th. Three investment analysts have rated the stock with a sell rating, five have assigned a hold rating and nine have given a buy rating to the company. Hologic has an average rating of “Hold” and an average target price of $44.87.
Hologic (NASDAQ:HOLX) last announced its earnings results on Wednesday, May 2nd. The medical equipment provider reported $0.53 earnings per share for the quarter, meeting the consensus estimate of $0.53. Hologic had a positive return on equity of 20.86% and a negative net margin of 4.15%. The firm had revenue of $789.30 million during the quarter, compared to the consensus estimate of $781.23 million. During the same quarter in the prior year, the company earned $0.50 EPS. The firm’s revenue for the quarter was up 10.3% compared to the same quarter last year. analysts anticipate that Hologic will post 2.23 EPS for the current year.
In related news, insider Peter J. Valenti III sold 10,107 shares of the stock in a transaction that occurred on Tuesday, May 29th. The stock was sold at an average price of $38.52, for a total transaction of $389,321.64. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, SVP Allison P. Bebo sold 7,000 shares of the firm’s stock in a transaction that occurred on Friday, March 16th. The stock was sold at an average price of $38.75, for a total value of $271,250.00. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 29,303 shares of company stock valued at $1,148,412. 0.88% of the stock is owned by corporate insiders.
Hologic Company Profile
Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women in the United States, Europe, the Asia-Pacific, and internationally. The company operates through five segments: Diagnostics, Breast Health, Medical Aesthetics, GYN Surgical, and Skeletal Health.
Receive News & Ratings for Hologic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hologic and related companies with MarketBeat.com's FREE daily email newsletter.